11/12
07:30 am
prok
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Medium
Report
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
11/5
07:30 am
prok
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
Medium
Report
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
10/18
11:47 am
prok
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate [Yahoo! Finance]
10/14
07:30 am
prok
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
Medium
Report
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
10/9
07:30 am
prok
ProKidney to Participate in the UBS Virtual Organ Restoration Day
Low
Report
ProKidney to Participate in the UBS Virtual Organ Restoration Day
9/30
08:15 am
prok
ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.
Low
Report
ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.
9/10
07:59 am
prok
ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock.
Low
Report
ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock.
9/4
01:26 pm
prok
ProKidney drops Phase III CKD study to focus on US market and save up to $175m [Yahoo! Finance]
Medium
Report
ProKidney drops Phase III CKD study to focus on US market and save up to $175m [Yahoo! Finance]
9/4
09:15 am
prok
ProKidney Corp. (NASDAQ: PROK) had its price target lowered by analysts at Bank of America Co. from $4.00 to $3.00. They now have a "neutral" rating on the stock.
Medium
Report
ProKidney Corp. (NASDAQ: PROK) had its price target lowered by analysts at Bank of America Co. from $4.00 to $3.00. They now have a "neutral" rating on the stock.
9/3
11:14 am
prok
ProKidney revises Phase 3 program for lead asset [Seeking Alpha]
Low
Report
ProKidney revises Phase 3 program for lead asset [Seeking Alpha]
9/3
07:44 am
prok
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. [Yahoo! Finance]
Medium
Report
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. [Yahoo! Finance]
9/3
07:30 am
prok
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
Low
Report
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
8/27
07:30 am
prok
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Medium
Report
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference